Current therapies to treat AD patients are based on the “cholinergic hypothesis” consisting of cholinesterase enzyme inhibition—acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). This evidence concerns the gene BCHE and Alzheimer disease.